Shenzhen TargetRx, Inc., a China-based developer of small-molecule kinase inhibitors, is poised to receive breakthrough therapy designation (BTD) for its Bcr-Abl inhibitor, TGRX-678, according to the China Center for Drug Evaluation (CDE) website. This designation recognizes the molecule’s promising potential for treating accelerated chronic myeloid leukemia (CML-AP) in patients who have undergone treatment with three or more generations of tyrosine kinase inhibitors (TKIs).
Currently, Bcr-Abl inhibitors approved for clinical use in leukemia treatment include first-generation imatinib and second-generation agents such as nilotinib, dasatinib, bosutinib, and flumatinib, along with third-generation ponatinib, which is not yet available in China.- Flcube.com
